Search research articles
Contact Us
Filters
Showing results (1-10 of 179) with videos related to
Page
of 18
Sort By:
Oncoimmunology
|
June 22, 2012
Modulation of DNA repair genes induced by TLR9 agonists: A strategy to eliminate "altered" cells?
Michele Sommariva, Loris De Cecco, Elda Tagliabue, et al.
Expert Review of Molecular Diagnostics
|
April 6, 2011
miRNA control of apoptotic programs: focus on ovarian cancer
Delia Mezzanzanica, Silvana Canevari, Loris De Cecco, et al.
Cancers
|
April 3, 2021
Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets
Loris De Cecco, Marina Bagnoli, Paolo Chiodini, et al.
The International Journal of Biochemistry & Cell Biology
|
December 29, 2009
Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications
Delia Mezzanzanica, Marina Bagnoli, Loris De Cecco, et al.
Current Treatment Options in Oncology
|
May 6, 2017
Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application?
Luca Tonella, Marco Giannoccaro, Salvatore Alfieri, et al.
Critical Reviews in Oncogenesis
|
April 26, 2013
Measuring microRNA expression levels in oncology: from samples to data analysis
Loris De Cecco, Matteo Dugo, Silvana Canevari, et al.
International Journal of Oncology
|
September 25, 2008
Clusterin: a potential target for improving response to antiestrogens
Sara Toffanin, Maria Grazia Daidone, Patrizia Miodini, et al.
Clinical Therapeutics
|
October 22, 2019
Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer
Carla Rognoni, Silvana Quaglini, Jan Baptist Vermorken, et al.
The Journal of Molecular Diagnostics : JMD
|
December 25, 2012
MicroRNA detection in plasma samples: how to treat heparinized plasma
Paola Tiberio, Loris De Cecco, Maurizio Callari, et al.
Genes
|
September 8, 2019
Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study
Matteo Dugo, Andrea Devecchi, Loris De Cecco, et al.
Page
of 18
Search research articles
Search
Showing results (1-10 of 179) with videos related to
Sort By:
Page
of 18
Oncoimmunology
|
June 22, 2012
Modulation of DNA repair genes induced by TLR9 agonists: A strategy to eliminate "altered" cells?
Michele Sommariva, Loris De Cecco, Elda Tagliabue, et al.
Expert Review of Molecular Diagnostics
|
April 6, 2011
miRNA control of apoptotic programs: focus on ovarian cancer
Delia Mezzanzanica, Silvana Canevari, Loris De Cecco, et al.
Cancers
|
April 3, 2021
Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets
Loris De Cecco, Marina Bagnoli, Paolo Chiodini, et al.
The International Journal of Biochemistry & Cell Biology
|
December 29, 2009
Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications
Delia Mezzanzanica, Marina Bagnoli, Loris De Cecco, et al.
Current Treatment Options in Oncology
|
May 6, 2017
Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application?
Luca Tonella, Marco Giannoccaro, Salvatore Alfieri, et al.
Critical Reviews in Oncogenesis
|
April 26, 2013
Measuring microRNA expression levels in oncology: from samples to data analysis
Loris De Cecco, Matteo Dugo, Silvana Canevari, et al.
International Journal of Oncology
|
September 25, 2008
Clusterin: a potential target for improving response to antiestrogens
Sara Toffanin, Maria Grazia Daidone, Patrizia Miodini, et al.
Clinical Therapeutics
|
October 22, 2019
Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer
Carla Rognoni, Silvana Quaglini, Jan Baptist Vermorken, et al.
The Journal of Molecular Diagnostics : JMD
|
December 25, 2012
MicroRNA detection in plasma samples: how to treat heparinized plasma
Paola Tiberio, Loris De Cecco, Maurizio Callari, et al.
Genes
|
September 8, 2019
Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study
Matteo Dugo, Andrea Devecchi, Loris De Cecco, et al.
Page
of 18